Robert L Rosenfield1. 1. Departments of Pediatrics and Medicine, Section of Adult and Pediatric Endocrinology, Metabolism, and Diabetes, The University of Chicago, Pritzker School of Medicine, Chicago, IL. Electronic address: robros@peds.bsd.uchicago.edu.
Abstract
BACKGROUND: Polycystic ovary syndrome (PCOS) is the most common cause of chronic hyperandrogenic anovulation. Two-thirds of PCOS patients have functionally typical PCOS, with typical functional ovarian hyperandrogenism manifest as 17-hydroxyprogesterone hyper-responsiveness to gonadotropin stimulation. Most, but not all, of the remainder have atypical functional ovarian hyperandrogenism. Many asymptomatic volunteers with polycystic ovary morphology (PCOM) have similar abnormalities. OBJECTIVE: The objective of this paper is to review the relationship of biochemical ovarian function to the clinical spectrum observed in PCOS and in normal volunteers with PCOM. FINDINGS: Adolescents and adults with PCOS are similar clinically and biochemically. Ninety-five percent of functionally typical PCOS have classic PCOS, ie, hyperandrogenic anovulation with PCOM. In addition to having more severe hyperandrogenism and a greater prevalence of PCOM than other PCOS, they have a significantly greater prevalence of glucose intolerance although insulin resistance is similarly reduced. Half of normal-variant PCOM have PCOS-related steroidogenic dysfunction, which suggests a PCOS carrier state. CONCLUSIONS: There is a spectrum of ovarian androgenic dysfunction that ranges from subclinical hyperandrogenemia in some normal-variant PCOM to severe ovarian hyperandrogenism in most classic PCOS. A minority of mild PCOS cases do not fall on this spectrum of ovarian androgenic dysfunction, but rather seem to have obesity as the basis of their hyperandrogenism, or, less often, isolated adrenal androgenic dysfunction. Half of normal-variant PCOM also do not fall on the PCOS spectrum, and some of these seem to have excessive folliculogenesis as a variant that may confer mild prolongation of the reproductive lifespan. Improved understanding of PCOM in young women is needed.
BACKGROUND:Polycystic ovary syndrome (PCOS) is the most common cause of chronic hyperandrogenic anovulation. Two-thirds of PCOSpatients have functionally typical PCOS, with typical functional ovarian hyperandrogenism manifest as 17-hydroxyprogesteronehyper-responsiveness to gonadotropin stimulation. Most, but not all, of the remainder have atypical functional ovarian hyperandrogenism. Many asymptomatic volunteers with polycystic ovary morphology (PCOM) have similar abnormalities. OBJECTIVE: The objective of this paper is to review the relationship of biochemical ovarian function to the clinical spectrum observed in PCOS and in normal volunteers with PCOM. FINDINGS: Adolescents and adults with PCOS are similar clinically and biochemically. Ninety-five percent of functionally typical PCOS have classic PCOS, ie, hyperandrogenic anovulation with PCOM. In addition to having more severe hyperandrogenism and a greater prevalence of PCOM than other PCOS, they have a significantly greater prevalence of glucose intolerance although insulin resistance is similarly reduced. Half of normal-variant PCOM have PCOS-related steroidogenic dysfunction, which suggests a PCOS carrier state. CONCLUSIONS: There is a spectrum of ovarian androgenic dysfunction that ranges from subclinical hyperandrogenemia in some normal-variant PCOM to severe ovarian hyperandrogenism in most classic PCOS. A minority of mild PCOS cases do not fall on this spectrum of ovarian androgenic dysfunction, but rather seem to have obesity as the basis of their hyperandrogenism, or, less often, isolated adrenal androgenic dysfunction. Half of normal-variant PCOM also do not fall on the PCOS spectrum, and some of these seem to have excessive folliculogenesis as a variant that may confer mild prolongation of the reproductive lifespan. Improved understanding of PCOM in young women is needed.
Authors: D Dewailly; H Gronier; E Poncelet; G Robin; M Leroy; P Pigny; A Duhamel; S Catteau-Jonard Journal: Hum Reprod Date: 2011-09-16 Impact factor: 6.918
Authors: Robert L Rosenfield; Monica Mortensen; Kristen Wroblewski; Elizabeth Littlejohn; David A Ehrmann Journal: Hum Reprod Date: 2011-09-09 Impact factor: 6.918
Authors: Janneke A Burgers; Sharon Lie Fong; Yvonne V Louwers; Olivier Valkenburg; Frank H de Jong; Bart C J M Fauser; Joop S E Laven Journal: J Clin Endocrinol Metab Date: 2010-09-15 Impact factor: 5.958
Authors: C Villarroel; P M Merino; P López; F C Eyzaguirre; A Van Velzen; G Iñiguez; E Codner Journal: Hum Reprod Date: 2011-07-21 Impact factor: 6.918
Authors: Madison T Ortega; Lauren Carlson; John A McGrath; Tairmae Kangarloo; Judith Mary Adams; Patrick M Sluss; Geralyn Lambert-Messerlian; Natalie D Shaw Journal: J Clin Endocrinol Metab Date: 2020-04-01 Impact factor: 5.958
Authors: Siri Atma W Greeley; Elizabeth Littlejohn; Aliya N Husain; Darrel Waggoner; Mohan Gundeti; Robert L Rosenfield Journal: Horm Res Paediatr Date: 2017-03-02 Impact factor: 2.852
Authors: Jee Young Jeong; Min Kyoung Kim; Inha Lee; Jisun Yun; Young Bin Won; Bo Hyon Yun; Seok Kyo Seo; SiHyun Cho; Young Sik Choi; Byung Seok Lee Journal: Obstet Gynecol Sci Date: 2019-07-22